Ellen Green

Qu Biologics is a Vancouver-based, private, clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel proprietary immunotherapy platform. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many diseases including cancer and inflammatory bowel disease (Crohn's disease, ulcerative colitis). SSIs aim to restore immune function and have potential broad applicability across a wide variety chronic diseases. The company has initiated three clinical trials in Crohn's disease, ulcerative colitis and lung cancer. Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally. We are always interested in talented biotechnology professionals and know that some of the best team members can be found when you’re not looking for them. For Qu, finding the right team member is not about matching a resume to a checklist of skills, it’s about integrity and character. If you have big ideas, love a fast-paced innovative environment and you’re up for the challenge, we want to hear from you. Send us your resume and a detailed cover letter telling us about yourself and how you feel you could contribute. Applications can be sent, in confidence, to [email protected].